Improvement of restless legs syndrome by varenicline as antismoking treatment

Andrea Romigi, Giuseppe Vitrani

Research output: Contribution to journalArticlepeer-review


Varenicline is a partial agonist at the α4β2 nicotinic acetylcholine receptor effective as smoking cessation pharmacotherapy. We present a familial case of severe restless legs syndrome (RLS) resistant to polytherapy who showed a consistent and effective amelioration of RLS symptoms after introduction of varenicline as antismoking drug.

Original languageEnglish
Pages (from-to)1089-1090
Number of pages2
JournalJournal of Clinical Sleep Medicine
Issue number10
Publication statusPublished - 2013


  • Nicotinic acetylcholine receptor agonist
  • Restless legs syndrome
  • Varenicline

ASJC Scopus subject areas

  • Clinical Neurology
  • Pulmonary and Respiratory Medicine
  • Neurology


Dive into the research topics of 'Improvement of restless legs syndrome by varenicline as antismoking treatment'. Together they form a unique fingerprint.

Cite this